Diabetes & Endocrinology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

This Phase 3 trial is testing a new combination drug called EloraTZP for adults who have both obesity or are overweight and type 2 diabetes. The goal is to see if EloraTZP can reduce body weight more effectively than existing treatments, which could help people better manage their weight and blood sugar levels. The study is large, involving 1000 participants from multiple countries, and will run for about two years to gather thorough results.

Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

This Phase 3 trial compares two injectable drugs for adults with type 2 diabetes: maridebart cafraglutide and semaglutide. Researchers want to find out if maridebart cafraglutide works as well as semaglutide but with the convenience of once-monthly dosing. If successful, this could mean fewer injections and easier blood sugar control for patients, especially those already using metformin with or without other diabetes medications. The study is currently recruiting participants in the United States and Canada.

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

This Phase 3 trial evaluates the same new combination drug, EloraTZP, but in adults with obesity who do not have type 2 diabetes. The aim is to find out if EloraTZP can help reduce weight more effectively or conveniently than current options. With plans to enroll over 2000 participants worldwide, this study could lead to a new treatment for weight management in people without diabetes, offering hope for improved health and quality of life.

Diabetes in African Youth

This Phase 4 study is focused on children and young adults with type 1 diabetes, testing continuous glucose monitors against traditional blood sugar testing methods. The goal is to determine if flash glucose monitoring can improve blood sugar control and be cost-effective, particularly in settings with fewer resources. This study is important for helping young people manage diabetes more easily and safely, and it is recruiting participants in the United States with a 12-month follow-up period.

A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

This Phase 2 trial is testing a new drug called LY4086940 to see if it can safely help adults with obesity or overweight who do not have type 2 diabetes lose weight. The study lasts about 58 weeks and is recruiting participants from several countries, including the United States and Argentina. If successful, LY4086940 could become a new option for weight management, offering more choices for people looking to improve their health.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.